<DOC>
	<DOCNO>NCT00902837</DOCNO>
	<brief_summary>The primary objective - demonstrate treatment OXN PR tablets non-inferior treatment OxyPR regard analgesic efficacy locomotor function . - demonstrate subject moderate severe OA pain take oxycodone/naloxone prolong release tablet improvement symptom constipation compare subject take oxycodone prolong release tablet alone</brief_summary>
	<brief_title>OXN PR Compared OxyPR Demonstrate Non-inferiority Pain &amp; Locomotor Function &amp; Improvement Symptoms Constipation OA Subjects</brief_title>
	<detailed_description>Subjects moderate severe pain due osteoarthritis ( OA ) randomise oxycodone/naloxone prolonged release ( OXN PR ) oxycodone prolong release tablet ( OxyPR ) alone demonstrate treatment OXN PR tablets non-inferior treatment OxyPR regard analgesic efficacy locomotor function demonstrate subject take OXN PR improvement symptom constipation compare subject take OxyPR alone .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Inclusion criterion : Moderate severe chronic nonmalignant OA require aroundtheclock opioid therapy . Exclusion criterion : Females pregnant lactate . Subjects evidence significant structural abnormality gastrointestinal tract . Subjects evidence impair liver/kidney function upon entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>randomise</keyword>
	<keyword>double-blind</keyword>
	<keyword>double-dummy</keyword>
	<keyword>parallel-group</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>pain locomotor function</keyword>
	<keyword>improvement symptom constipation</keyword>
	<keyword>moderate severe pain due osteoarthritis ( OA )</keyword>
	<keyword>OXN PR</keyword>
	<keyword>OxyPR</keyword>
	<keyword>Moderate severe chronic nonmalignant OA</keyword>
</DOC>